Dysgeusia News and Research

RSS

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

Researchers presented the results of a phase III randomized controlled trial of oral SARS-CoV-2 antiviral VV116.

3 Jan 2023

What are the risk factors associated with symptomatic SARS-CoV-2 and rhinovirus infection in King County, Washington, from June 2020 to July 2022?

Researchers evaluated the change in symptoms and risk factors associated with positive SARS-CoV-2 tests during the COVID-19 pandemic and compared it to those associated with positive tests of other respiratory viruses among residents of King County, Washington, in the United States.

14 Dec 2022

Study explores histopathological, serological, and clinical characteristics of PASC in patients with mild COVID-19

Researchers investigated the clinical, histopathological, imaging, and serological characteristics of post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) in patients with mild COVID-19.

5 Dec 2022

SARS-CoV-2 Omicron infections pose long-COVID risks despite reduced severity

researchers compared the post-coronavirus disease complaints and symptoms in individuals infected with the SARS-CoV-2 Omicron variant with those in individuals with Delta variant infections to understand whether the long-term complaints after Omicron infections are similar to those in infections with other SARS-CoV-2 variants.

2 Dec 2022

Long COVID brain fog and fatigue negatively impact all facets of daily life

In a recent study published in the International Journal of Environmental Research and Public Health, researchers explored the lived experiences of individuals with post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) to understand the impact of the symptoms such as fatigue and brain fog on the various aspects of life including employment, daily activities, and interpersonal relationships.

27 Nov 2022

Short-term outcomes in pregnant patients with COVID-19 who received nirmatrelvir–ritonavir treatment

Researchers investigated the short-term outcomes of treating pregnant patients exhibiting mild to moderate symptoms of COVID-19 with Paxlovid, which is a combination of the antivirals nirmatrelvir and ritonavir.

15 Nov 2022

Exploring the safety and immunogenicity of KD-414, a novel SARS-CoV-2 vaccine

In a new study, researchers assessed the immunogenicity and safety of KD-414, an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

1 Nov 2022

Longitudinal cohort study of primary healthcare workers reveals long-lasting SARS-CoV-2 humoral immunity in the absence of vaccination

Researchers performed a longitudinal cohort study to assess the levels of immunoglobulins M (IgM), G (IgG), and A (IgA) against the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Oct 2022

Danish study shows 3rd booster dose reduces risk of long-COVID

A recent study posted to the medRxiv* preprint server found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the Omicron variant predominant period was associated with post-acute symptoms of coronavirus disease 2019 (COVID-19) or ‘long COVID’, as well general health problems with new onset – four months after a COVID-19 positive test result.

17 Oct 2022

Increased TMPRSS2 expression in tongue tissue of females and alcohol drinkers identified as a potential risk factor for SARS-CoV-2 infection

Researchers explored the association between the expressions of the ACE-2 receptor and TMPRSS2 in the tongue tissue and dysgeusia during SARS-CoV-2 infections.

17 Oct 2022

Dysgeusia News and Research

Phase III trial shows noninferiority of VV116 compared to nirmatrelvir–ritonavir among adults with mild-to-moderate COVID-19 at risk of progression

What are the risk factors associated with symptomatic SARS-CoV-2 and rhinovirus infection in King County, Washington, from June 2020 to July 2022?

Study explores histopathological, serological, and clinical characteristics of PASC in patients with mild COVID-19

SARS-CoV-2 Omicron infections pose long-COVID risks despite reduced severity

Long COVID brain fog and fatigue negatively impact all facets of daily life

Short-term outcomes in pregnant patients with COVID-19 who received nirmatrelvir–ritonavir treatment

Exploring the safety and immunogenicity of KD-414, a novel SARS-CoV-2 vaccine

Longitudinal cohort study of primary healthcare workers reveals long-lasting SARS-CoV-2 humoral immunity in the absence of vaccination

Danish study shows 3rd booster dose reduces risk of long-COVID

Increased TMPRSS2 expression in tongue tissue of females and alcohol drinkers identified as a potential risk factor for SARS-CoV-2 infection

What is the association of SARS-CoV-2 vaccination with the risk of PASC in patients with SARDs?

Study shows astrocytes as breeding grounds of SARS-CoV-2 during brain infection

How common is chronic fatigue syndrome among patients with long COVID-19?

The possible immune-mediated mechanisms causing CNS alterations during and post-acute SARS-CoV-2 infection

Profound neuroinflammation associated with long COVID

Neurological symptoms may persist for over one year in long-COVID patients

Prevalence of long COVID-19 after Omicron infection

What are the long-term symptoms of SARS-CoV-2 infection?

Long COVID symptoms in families a year after SARS-CoV-2 infection or household exposure

SARS-CoV-2 Mpro inhibitor, nirmatrelvir, found to reduce COVID-19 progression and death

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News